Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine

Three major forms of the nicotinic agonist toxin anabaseine (cyclic iminium, cyclic imine and the monocationic open-chain ammonium-ketone) co-exist in almost equal concentrations at physiological pH. We asked the question: Which of these forms is pharmacologically active? First, we investigated the...

Full description

Bibliographic Details
Main Authors: Kristin Andrud, Hong Xing, Bjarne Gabrielsen, Linda Bloom, Vladimir Mahnir, Stephen Lee, Benedict T. Green, Jon Lindstrom, William Kem
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Marine Drugs
Subjects:
Online Access:https://www.mdpi.com/1660-3397/17/11/614
id doaj-b7c84c2e21d741a98204f26dc3caed1b
record_format Article
spelling doaj-b7c84c2e21d741a98204f26dc3caed1b2020-11-25T01:38:40ZengMDPI AGMarine Drugs1660-33972019-10-01171161410.3390/md17110614md17110614Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist AnabaseineKristin Andrud0Hong Xing1Bjarne Gabrielsen2Linda Bloom3Vladimir Mahnir4Stephen Lee5Benedict T. Green6Jon Lindstrom7William Kem8Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USADepartment of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USADepartment of Chemistry, University of Florida, Gainesville, FL 32610, USADepartment of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL 32610; USADepartment of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USAUSDA-ARS Poisonous Plant Research Laboratory, Logan, UT 84341, USAUSDA-ARS Poisonous Plant Research Laboratory, Logan, UT 84341, USADepartment of Neuroscience, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL 32610, USAThree major forms of the nicotinic agonist toxin anabaseine (cyclic iminium, cyclic imine and the monocationic open-chain ammonium-ketone) co-exist in almost equal concentrations at physiological pH. We asked the question: Which of these forms is pharmacologically active? First, we investigated the pH dependence of anabaseine inhibition of [<sup>3</sup>H]-methylcarbamylcholine binding at rat brain &#945;4&#946;2 nicotinic acetylcholine receptors (nAChRs). These experiments indicated that one or both monocationic forms interact with the orthosteric binding site for ACh. However, since they occur at equal concentrations near physiological pH, we employed another approach, preparing a stable analog of each form and examining its agonist activities and binding affinities at several vertebrate brain and neuromuscular nAChRs. Only 2-(3-pyridyl)-1,4,5,6-tetrahydropyrimidine monohydrogen chloride (PTHP), the cyclic iminium analog, displayed nAChR potencies and binding affinities similar to anabaseine. The cyclic imine analog 2,3&#8242;-bipyridyl and the open-chain ammonium-ketone analog 5-methylamino-1-(3-pyridyl)-1-pentanone (MAPP), displayed &#8804;1% of the activity predicted if the one form was solely active. The lower potency of weakly basic 2,3&#8242;-bipyridyl can be explained by the presence of a small concentration of its monocationic form. Since the open chain ammonium-ketone monocationic form of anabaseine has some structural similarity to the neurotransmitter GABA, we also tested the ability of anabaseine and its 1,2-dehydropyrrolidinyl analog myosmine to activate a mammalian GABA<sub>A</sub> receptor, but no activity was detected. We conclude that the monocationic cyclic iminium is the form which avidly binds and activates vertebrate nAChRs.https://www.mdpi.com/1660-3397/17/11/614acetylcholinealkaloidanabaseinebipyridylcholinergicnicotinenicotinic acetylcholine receptorring-chain tautomerismtoxin
collection DOAJ
language English
format Article
sources DOAJ
author Kristin Andrud
Hong Xing
Bjarne Gabrielsen
Linda Bloom
Vladimir Mahnir
Stephen Lee
Benedict T. Green
Jon Lindstrom
William Kem
spellingShingle Kristin Andrud
Hong Xing
Bjarne Gabrielsen
Linda Bloom
Vladimir Mahnir
Stephen Lee
Benedict T. Green
Jon Lindstrom
William Kem
Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine
Marine Drugs
acetylcholine
alkaloid
anabaseine
bipyridyl
cholinergic
nicotine
nicotinic acetylcholine receptor
ring-chain tautomerism
toxin
author_facet Kristin Andrud
Hong Xing
Bjarne Gabrielsen
Linda Bloom
Vladimir Mahnir
Stephen Lee
Benedict T. Green
Jon Lindstrom
William Kem
author_sort Kristin Andrud
title Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine
title_short Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine
title_full Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine
title_fullStr Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine
title_full_unstemmed Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine
title_sort investigation of the possible pharmacologically active forms of the nicotinic acetylcholine receptor agonist anabaseine
publisher MDPI AG
series Marine Drugs
issn 1660-3397
publishDate 2019-10-01
description Three major forms of the nicotinic agonist toxin anabaseine (cyclic iminium, cyclic imine and the monocationic open-chain ammonium-ketone) co-exist in almost equal concentrations at physiological pH. We asked the question: Which of these forms is pharmacologically active? First, we investigated the pH dependence of anabaseine inhibition of [<sup>3</sup>H]-methylcarbamylcholine binding at rat brain &#945;4&#946;2 nicotinic acetylcholine receptors (nAChRs). These experiments indicated that one or both monocationic forms interact with the orthosteric binding site for ACh. However, since they occur at equal concentrations near physiological pH, we employed another approach, preparing a stable analog of each form and examining its agonist activities and binding affinities at several vertebrate brain and neuromuscular nAChRs. Only 2-(3-pyridyl)-1,4,5,6-tetrahydropyrimidine monohydrogen chloride (PTHP), the cyclic iminium analog, displayed nAChR potencies and binding affinities similar to anabaseine. The cyclic imine analog 2,3&#8242;-bipyridyl and the open-chain ammonium-ketone analog 5-methylamino-1-(3-pyridyl)-1-pentanone (MAPP), displayed &#8804;1% of the activity predicted if the one form was solely active. The lower potency of weakly basic 2,3&#8242;-bipyridyl can be explained by the presence of a small concentration of its monocationic form. Since the open chain ammonium-ketone monocationic form of anabaseine has some structural similarity to the neurotransmitter GABA, we also tested the ability of anabaseine and its 1,2-dehydropyrrolidinyl analog myosmine to activate a mammalian GABA<sub>A</sub> receptor, but no activity was detected. We conclude that the monocationic cyclic iminium is the form which avidly binds and activates vertebrate nAChRs.
topic acetylcholine
alkaloid
anabaseine
bipyridyl
cholinergic
nicotine
nicotinic acetylcholine receptor
ring-chain tautomerism
toxin
url https://www.mdpi.com/1660-3397/17/11/614
work_keys_str_mv AT kristinandrud investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT hongxing investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT bjarnegabrielsen investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT lindabloom investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT vladimirmahnir investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT stephenlee investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT benedicttgreen investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT jonlindstrom investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
AT williamkem investigationofthepossiblepharmacologicallyactiveformsofthenicotinicacetylcholinereceptoragonistanabaseine
_version_ 1725052226494267392